What is Cruise & Blast cycling and why is Drostanolone Propionate used in it?

Cruise & Blast is a periodised performance protocol that alternates between higher-dose blast phases — designed to maximise anabolic stimulus — and lower-dose cruise phases intended to preserve gains while allowing partial hormonal recovery. Drostanolone Propionate is used in this structure because its short ester allows dose adjustments to take effect within days, giving athletes precise control over androgenic load at each phase transition.

How long should the cruise phase last when running Mastebol as part of a Cruise & Blast programme?

Most structured Cruise & Blast frameworks place the cruise phase at eight to twelve weeks, long enough to allow meaningful reduction in suppression depth and recovery of endogenous signalling pathways before the next intensification block. Mastebol's 100mg/ml concentration makes it straightforward to dial cruise doses down to 100–150mg per week using half-millilitre or three-quarter-millilitre injections on an every-other-day schedule.

When is the right point to switch from a blast back to a cruise when using Drostanolone Propionate?

The transition signal is typically a combination of time-based criteria — eight to twelve weeks at blast dose — and physiological markers such as declining training recovery quality, haematocrit trending toward the upper threshold, or lipid panels warranting a reduction in total androgen load. Because Drostanolone Propionate clears within approximately five to seven days of the final injection, the drop from blast to cruise serum levels happens rapidly once injection frequency or per-dose volume is reduced.

What is the advantage of 100mg/ml concentration for Cruise & Blast compared to higher-concentration formulations?

At 100mg/ml, Mastebol is the lowest-concentration Drostanolone Propionate option in this product group, which makes it the most granular for dose titration across phase transitions. Reducing from a 300mg blast to a 100–150mg cruise involves moving from 1ml per injection three times weekly to 0.5ml — a straightforward volume change that minimises measurement imprecision when precision matters most at phase boundaries.

How does the 10x1ml single-dose ampoule format benefit athletes running multi-phase Cruise & Blast programmes?

Each 1ml glass ampoule is factory-sealed and opened once at the point of injection, which means every draw — whether during a high-frequency blast phase or a reduced-frequency cruise phase — comes from a sterile, never-previously-accessed environment. There is no multi-dose vial to maintain sterility across weeks of changing injection schedules, reducing contamination risk during the frequent dose adjustments that characterise structured phase-cycling protocols. (2) angle_used

Advanced Formula

Omega Meds

Mastebol 100mg/ml 10x1ml Ampullen by Omega Meds

Name: Mastebol 100mg/ml 10x1ml Ampoules by Omega Meds
Brand: Omega Meds
SKU: INJ-DROP-OME-100-015
Price: 45.00 EUR
Availability: InStock

Mastebol is a single-dose injectable Drostanolone Propionate formulation at 100mg/ml, engineered specifically to serve structured Cruise & Blast programming where clear anabolic phase separation demands a short-ester androgen with predictable entry and exit kinetics. Ten individually sealed 1ml glass ampoules deliver dose-accurate, sterile draws on every injection day — whether the athlete is in an intensified blast or a conservative cruise maintenance window. Lot-specific quality release is enforced through HPLC potency assay and LAL endotoxin testing; every ampoule batch must pass both protocols before leaving the production facility.

€45.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Rapid phase-transition capability — androgenic load adjusts within days when moving between blast and cruise windows
Single-dose ampoule integrity eliminates sterility concerns across weeks of variable injection scheduling
100mg/ml granularity supports precise dose reduction from blast totals to cruise maintenance levels
SHBG displacement amplifies the net androgenic environment during blast phases without escalating co-administered compound doses
Non-aromatising androgenic profile maintains a dry, vascular physique across both blast and cruise phases
Lot-specific HPLC and LAL documentation enables confident stacking decisions when multiple compounds run simultaneously
Two-to-three-day half-life provides dose-response feedback within the same injection week, enabling real-time phase adjustments

Phase	Weekly Dose	Injection Frequency	Note
Blast – Intensification	300–400mg	Every other day (EOD)	Paired with a testosterone base; HPLC-confirmed 100mg/ml allows exact EOD volumes of 1.0ml per injection at 300mg/week
Cruise – Maintenance	100–150mg	3× per week or EOD	Half-millilitre draws at 100mg/ml provide 50mg per injection — sufficient androgenic maintenance signal without deep suppression
Blast-to-Cruise Transition	Taper 300mg → 150mg over 1 week	EOD	Propionate ester kinetics allow effective serum-level reduction within 5–7 days; no extended tapering window required
Pre-PCT Exit (end of final cruise)	Reduce to 50–75mg final week	2× final week	Final injection timed to allow clearance before PCT start; single-dose ampoules support this low-frequency exit cleanly

Key takeaways

Structure blast and cruise phases precisely using Mastebol's rapid ester clearance.
Reduce weekly dose to 100–150mg during cruise without complex volume calculations.
Switch phase-to-phase within days, not weeks, thanks to the propionate ester.
Use single-dose ampoules to maintain sterility across changing injection schedules.
Confirm every batch via HPLC potency data and LAL endotoxin documentation.

Mastebol in Cruise & Blast Protocols: The Case for a Short-Ester Androgenic Anchor

Mastebol by Omega Meds is a parenteral Drostanolone Propionate preparation — 100mg/ml across ten sealed 1ml ampoules — designed to function as the androgenic anchor within a periodised Cruise & Blast programming model that alternates between high-anabolic blast phases and lower-dose cruise maintenance windows. Unlike protocols built around a single uninterrupted run, Cruise & Blast architecture separates distinct physiological objectives: the blast phase maximises muscle stimulus through elevated androgen saturation, while the cruise phase preserves accumulated lean mass at doses low enough to allow partial hormonal recovery. Drostanolone Propionate's two-to-three-day biological half-life makes it particularly suited to this structure because the athlete can adjust effective androgen load between phases within days rather than weeks — a pharmacokinetic advantage that longer-ester compounds cannot offer in the same timeframe.

Blast Phase Application: Androgenic Density Without Aromatisation Risk

During the blast phase, Mastebol delivers a hardening and drying effect alongside the primary anabolic compounds in the stack. Drostanolone Propionate competes with endogenous androgens for SHBG binding sites, raising the free fraction of co-administered testosterone without requiring a testosterone dose increase — a documented mechanism that intensifies the net androgenic environment during high-volume training blocks. Compared to non-aromatising orals sometimes introduced during blast phases, Drostanolone Propionate provides persistent androgen receptor engagement across multiple injection days per week without hepatotoxic burden, making it sustainable across a full 8–12 week intensification block.

Cruise Phase Application: Minimum Effective Androgen Maintenance

The cruise phase demands hormonal economy — enough androgenic input to preserve lean tissue and support recovery, but low enough total load to permit gradual normalisation of endogenous feedback. Mastebol at reduced weekly totals (typically 100–150mg per week during cruise) provides that maintenance signal without the suppressive depth of higher blast doses. The propionate ester clears systemically within approximately five to seven days of the final injection, giving the athlete a clean transition window when the programme moves from blast back to cruise — or eventually toward PCT. Omega Meds' ampoule format aligns directly with this phase-change flexibility: single-use glass ampoules eliminate carry-over contamination risk when dose and frequency shift between phases.

Manufacturing Verification

Omega Meds applies reversed-phase HPLC assay at the batch level to confirm that Drostanolone Propionate content in Mastebol matches the declared 100mg/ml concentration; a separate LAL (Limulus Amebocyte Lysate) endotoxin test is performed on each production lot before release. These two quality gates — potency and parenteral safety — are documented per lot number, allowing end users to verify the specific batch accompanying their product.

Usage

Define your phase structure before beginning: decide blast duration (typically 8–12 weeks), cruise duration (8–12 weeks), and the total number of cycles in the programme before the first injection.
During the blast phase, draw a fresh sealed 1ml ampoule for each EOD injection; snap the ampoule neck cleanly, draw the full 1ml (100mg) or partial volume per your target dose, and administer intramuscularly into a rotating site.
Maintain EOD frequency throughout the blast phase to keep serum Drostanolone Propionate levels stable between injections, consistent with the compound's two-to-three-day half-life window.
At the phase transition point, reduce per-injection volume and/or injection frequency to cruise parameters within the same injection week — the propionate ester's clearance speed allows the dose change to register in serum levels within three to five days.
During the cruise phase, continue using individual sealed ampoules for each injection; do not store partially used ampoules between injection days — discard any unused portion from a broken-seal ampoule immediately.
Log each injection date, volume, and lot number against your bloodwork schedule; mid-cruise haematological markers (haematocrit, lipid panel, testosterone suppression) should guide the decision to extend the cruise or proceed to the next blast.

Warnings

Contraindications: Mastebol is contraindicated in individuals with androgen-sensitive prostate conditions, existing cardiovascular disease, elevated haematocrit above 54%, or a confirmed hypersensitivity to Drostanolone Propionate or the carrier oil. Women of childbearing potential should not use this compound due to virilisation risk.

Side Effects: Androgenic effects including accelerated scalp hair recession in genetically predisposed individuals, increased skin sebum output, and potential aggravation of benign prostatic changes are the primary class-related concerns. HDL cholesterol suppression occurs with androgenic compounds; frequency of lipid monitoring should increase during blast phases when weekly doses are elevated. Injection-site localised reactions are possible and mitigated by site rotation.

Monitoring: Haematocrit and haemoglobin should be assessed at the start of each blast phase and at the mid-point; lipid panels (HDL, LDL, total cholesterol) are recommended at the same intervals. Blood pressure monitoring is advisable throughout both blast and cruise phases. Liver enzyme panels are prudent when Mastebol is stacked with hepatotoxic compounds, even though Drostanolone Propionate itself is not a 17-alpha alkylated compound.

PCT: Following the final cruise phase, post-cycle therapy should be initiated after allowing adequate clearance time — typically five to seven days following the last Mastebol injection. Standard PCT agents (SERMs such as Tamoxifen or Clomiphene) are appropriate. The duration and intensity of PCT should reflect total programme length and suppression depth across all cruise and blast phases completed.

Frequently asked questions

What is Cruise & Blast cycling and why is Drostanolone Propionate used in it?: Cruise & Blast is a periodised performance protocol that alternates between higher-dose blast phases — designed to maximise anabolic stimulus — and lower-dose cruise phases intended to preserve gains while allowing partial hormonal recovery. Drostanolone Propionate is used in this structure because its short ester allows dose adjustments to take effect within days, giving athletes precise control over androgenic load at each phase transition.
How long should the cruise phase last when running Mastebol as part of a Cruise & Blast programme?: Most structured Cruise & Blast frameworks place the cruise phase at eight to twelve weeks, long enough to allow meaningful reduction in suppression depth and recovery of endogenous signalling pathways before the next intensification block. Mastebol's 100mg/ml concentration makes it straightforward to dial cruise doses down to 100–150mg per week using half-millilitre or three-quarter-millilitre injections on an every-other-day schedule.
When is the right point to switch from a blast back to a cruise when using Drostanolone Propionate?: The transition signal is typically a combination of time-based criteria — eight to twelve weeks at blast dose — and physiological markers such as declining training recovery quality, haematocrit trending toward the upper threshold, or lipid panels warranting a reduction in total androgen load. Because Drostanolone Propionate clears within approximately five to seven days of the final injection, the drop from blast to cruise serum levels happens rapidly once injection frequency or per-dose volume is reduced.
What is the advantage of 100mg/ml concentration for Cruise & Blast compared to higher-concentration formulations?: At 100mg/ml, Mastebol is the lowest-concentration Drostanolone Propionate option in this product group, which makes it the most granular for dose titration across phase transitions. Reducing from a 300mg blast to a 100–150mg cruise involves moving from 1ml per injection three times weekly to 0.5ml — a straightforward volume change that minimises measurement imprecision when precision matters most at phase boundaries.
How does the 10x1ml single-dose ampoule format benefit athletes running multi-phase Cruise & Blast programmes?: Each 1ml glass ampoule is factory-sealed and opened once at the point of injection, which means every draw — whether during a high-frequency blast phase or a reduced-frequency cruise phase — comes from a sterile, never-previously-accessed environment. There is no multi-dose vial to maintain sterility across weeks of changing injection schedules, reducing contamination risk during the frequent dose adjustments that characterise structured phase-cycling protocols. (2) angle_used

Manufacturer

Quality verification at Omega Meds operates at the lot level rather than the product-family level — a structural distinction that matters when an athlete is simultaneously managing multiple injectable compounds across a Cruise & Blast programme and needs confidence that each individual batch conforms to its label. For Mastebol specifically, two independent analytical gates are applied before any ampoule reaches distribution: reversed-phase HPLC quantification of Drostanolone Propionate content against a reference standard, confirming the declared 100mg/ml concentration; and LAL (Limulus Amebocyte Lysate) endotoxin testing confirming parenteral safety at lot-specific thresholds. Both results are tied to the production lot number accompanying the product, meaning the data is traceable to the exact ampoules in the user's hands rather than to a generic product specification. This batch-individualised documentation approach reflects the manufacturing philosophy Omega Meds applies across its injectable portfolio: every release decision is compound-specific, lot-specific, and independently verified.

Product details

Brand	Omega Meds
Active ingredient	drostanolone propionate
Also known as	Masteron, Drolban, Drostanolone Propionate, Mastebol, Omega Meds Masteron
Strength	100 mg
Form	Ampullen
Pack size	10 pieces
Item number	INJ-DROP-OME-100-015

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Masteron is an oil-based injectable solution delivering Drostanolone Propionate at 100mg/ml, distinguished by its capacity to bypass hepatic first-pass metabolism entirely — a pharmacokinetic advantage that oral androgen compounds cannot replicate. Each 10ml multi-dose vial provides a full cycle's supply of pharmaceutical-grade active, with systemic absorption occurring directly through intramuscular tissue into the bloodstream. Quality assurance is built into every lot: HPLC potency verification, LAL endotoxin screening, and GMP-certified filling suites are standard — not optional — at Beligas Pharmaceuticals.

€46.00

Masten-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Masten-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-100 is a fast-acting injectable androgenic compound delivering Drostanolone Propionate at 100mg/ml in single-dose 1ml ampoules, specifically engineered for rapid tissue uptake and measurable efficacy within the first days of administration. The propionate ester's short carbon chain enables peak plasma concentrations to establish quickly — typically within 24–48 hours of the first injection — making it one of the fastest-onset drostanolone formulations available. Every lot is released only after HPLC potency confirmation and LAL endotoxin screening; sterility is assured via Ph. Eur. 2.6.1-compliant testing conducted at BM Pharmaceuticals' GMP-certified facility.

€47.00

High Concentration

MasterTrex 150mg/ml 10ml Vial by Concentrex Labs

MasterTrex is a high-concentration Drostanolone Propionate injectable, formulated at 150 mg/ml in a 10 ml multi-dose vial and engineered for athletes who demand precise, schedule-driven injection timing across their cutting or pre-contest phase. At 150 mg/ml, each draw delivers a clinically meaningful dose in a compact volume, making every-other-day or every-third-day scheduling straightforward without excess injection site load. Quality is locked in at batch level: HPLC-quantified potency verification and LAL endotoxin testing are completed before any MasterTrex vial leaves the Concentrex Labs facility.

€50.00

Brand Quality

Masteron 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 100 is a drostanolone propionate injectable solution at 100mg/ml in a 10ml multi-dose vial, specifically suited to frontloading protocols that compress the time-to-steady-state window at the opening of a cycle. Because the propionate ester releases active drostanolone within a short half-life of approximately 2–3 days, calculated loading doses can bring circulating androgen levels to the target therapeutic range within the first 72 hours rather than waiting the usual week or more. Dragon-Pharma batch-releases every vial only after HPLC potency verification and LAL endotoxin clearance — two independent quality gates applied sequentially before product leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00